Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy

Intervirology

Volumn 49, Issue 6, 2006, Pages 352-361

  Arataki, Keiko ^a   Kumada, Hiromitsu ^b   Toyota, Kiyomi ^c   Ohishi, Waka ^c   Takahashi, Shoichi ^c   Tazuma, Susumu ^c   Chayama, Kazuaki ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C virus infection; Error catastrophe; Hepatitis C virus quasispecies; Ribavirin; Viral resistance

Indexed keywords

ALPHA2B INTERFERON; COMPLEMENTARY DNA; ENVELOPE PROTEIN; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; MUTAGENIC AGENT; NUCLEOSIDE ANALOG; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; VIRUS ENZYME; VIRUS PROTEIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC DISTANCE; GENETIC DRIFT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MOLECULAR CLONING; MOLECULAR EVOLUTION; MONOTHERAPY; PHYLOGENY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECIES; UNTRANSLATED REGION; VIRUS GENOME;

5' UNTRANSLATED REGIONS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EVOLUTION, MOLECULAR; GENETIC DRIFT; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MUTATION; PHYLOGENY; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 33749618635     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095155     Document Type: Article

References (33)

1. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis. N Engl J Med 1995;332:1463-1466.
2. Kim WR: The burden of hepatitis C in the United States. Hepatology 2002;36(suppl 1): S30-S34.
3. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-1431.
4. Kiyosawa K, Tanaka E: Characteristics of hepatocellular carcinoma in Japan. Oncology 2002;62(suppl 1):5-7.
5. McHutchison JG, Gordon SC, Schiff ER, Shiftman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
7. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-1499.
8. Lau JYN, Tam RC, Liang TJ, Hong Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-1009.
9. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE: The broad-spectram antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
10. Crotty S, Cameron CE, Andino R: RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001;98:6895-6900.
11. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT: Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002;76:8505-8517.
12. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR: The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003;310:333-342.
13. Sookoian S, Castano G, Frider B, Cello J, Campos R, Flichman D: Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity. Dig Dis Sci 2001;46:1067-1071.
14. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, Hofgartner WT, Carithers RL Jr, McMahon BJ, Mullins JI, Corey L, Gretch DR: Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998;72:4288-4296.
15. Pawlotsky JM, Germanidis G, Frainais PO, Bouvier M, Soulier A, Pellerin M, Dhumeaux D: Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999;73:6490-6499.
16. Bassett SE, Thomas DL, Bransly KM, Lanford RE: Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J Virol 1999;73:1118-1126.
17. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, Polyak SJ, Gretch DR, Katze MG: Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997;230:217-227.
18. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D: Interferon resistance of hepatitis C virus genotype 1b:relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998;72:2795-2805.
19. Behrens SE, Tomei L, De Francesco R: Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12-22.
20. Lohmann V, Korner F, Herian U, Bartenschlager R: Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997;71:8416-8428.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
22. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotohno K: Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A. non-B hepatitis. Proc Natl Acad Sci USA 1990;87:9524-9528.
23. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980;16:111-120.
24. Kumar S, Tamura K, Jakobsen IB, Nei M: MEGA2: Molecular Evolutionary Genetics Analysis software. Bioinformatics, 2001.
25. Saitou N, Nei M: The neighbor-joining method: a new method for reconstruction phylogenetic trees. Mol Biol Evol 1987;4:406-425.
26. Felsenstein J: Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39.783-791.
27. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E: Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 2003;311:339-349.
28. Querenghi F, Yu Q, Billaud G, Maertens G, Trepo C, Zoulim F: Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J Viral Hepatol 2001;8:120-131.
29. Balzarini J, Wedgwood O, Kruining J, Pelemans H, Heijtink R, De Clercq E, McGuigan C: Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996;225:363-369.
30. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ: Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
31. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-717.
32. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
33. Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S: Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998;29:29-35.